| Oligodendrogliopathy in multiple sclerosis: low glycolytic metabolic rate promotes oligodendrocyte survival MB Rone, QL Cui, J Fang, LC Wang, J Zhang, D Khan, M Bedard, ... Journal of Neuroscience 36 (17), 4698-4707, 2016 | 107 | 2016 |
| Harnessing the power of invariant natural killer T cells in cancer immunotherapy M Bedard, M Salio, V Cerundolo Frontiers in immunology 8, 308005, 2017 | 57 | 2017 |
| Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells M Bedard, D Shrestha, DA Priestman, Y Wang, F Schneider, JD Matute, ... Proceedings of the National Academy of Sciences 116 (47), 23671-23681, 2019 | 29 | 2019 |
| Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2 BA Trombetta, SE Kandigian, RR Kitchen, K Grauwet, PK Webb, GA Miller, ... BMC infectious diseases 21 (1), 580, 2021 | 24 | 2021 |
| Enhanced immunogenicity of mitochondrial-localized proteins in cancer cells G Prota, U Gileadi, M Rei, AV Lechuga-Vieco, JL Chen, S Galiani, ... Cancer Immunology Research 8 (5), 685-697, 2020 | 11 | 2020 |
| THE EPI-R-TM TECHNOLOGY PRODUCES A POLYCLONAL TIL PRODUCT (LYL845) WITH A GREATER EXPANSION SUCCESS RATE ACROSS HOT AND COLD TUMORS, IMPROVED PRODUCT PHENOTYPE, AND MAINTENANCE … Y Patel, B Harris, M Bedard, J Kritikou, MG Casas, C Harms, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A389-A389, 2022 | 4 | 2022 |
| Oligodendrogliopathy in Multiple Sclerosis: Relation to Low Glycolytic Metabolic Rate of Oligodendrocytes (S2. 003) QL Cui, M Rone, D Khan, M Bedard, G Almazan, S Ludwin, T Kennedy, ... Neurology 86 (16_supplement), S2. 003, 2016 | 4 | 2016 |
| 379 Epi-RTM P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time Y Patel, J Yun, M Bedard, M DeFrancesco, C Harms, B Harris, S Azimi, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract A54: Epi-RTM (epigenetic reprogramming) technology improves stemness, preserves polyclonality and enhances antitumor functionality of tumor … Y Patel, NH Ha, M Bedard, J Kritikou, R Kishton, SK Vodnala Cancer Immunology Research 10 (12_Supplement), A54-A54, 2022 | | 2022 |
| Epi-R (TM)(epigenetic reprogramming) technology improves stemness, preserves polyclonality and enhances antitumor functionality of tumor infiltrating lymphocytes in nonclinical … Y Patel, NH Ha, M Bedard, J Kritikou, R Kishton, SK Vodnala CANCER IMMUNOLOGY RESEARCH 10 (12), 2022 | | 2022 |
| 370 The Epi-RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and … Y Patel, B Harris, M Bedard, J Kritikou, MG Casas, C Harms, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2 (preprint) BA Trombetta, SE Kandigian, RR Kitchen, K Grauwet, PK Webb, GA Miller, ... | | 2021 |
| Enhanced immunogenicity of mitochondrial localised proteins in cancer cells G Prota, U Gileadi, M Rei, AV Lechuga-Vieco, JL Chen, S Galiani, ... EUROPEAN JOURNAL OF IMMUNOLOGY 49, 1519-1519, 2019 | | 2019 |
| Distinct energy utilization properties of human oligodendrocytes and oligodendrocyte progenitor cells (OPCs) as determinants of their susceptibility to injury in multiple sclerosis M Rone, QL Cui, M Bedard, H McBride, J Zhang, V Rao, G Almazan, ... MULTIPLE SCLEROSIS JOURNAL 21, 425-425, 2015 | | 2015 |
| Epi-R™ P2 Protocol Produces a Scalable Polyclonal TIL Product With a Greater Expansion Success Rate Across Hot and Cold Tumors in Shorter Culture Time Y Patel, M Bedard, J Yun, A Garces, S Azimi, M Min, S Chan, NH Ha, T Ta, ... population 500, 4-1BB, 0 | | |
